Sodium oxybate

Not to be confused with Xywav.

Sodium oxybate

Clinical data
Trade names	Xyrem, Alcover, Somsanit, others
Other names	NSC-84223, WY-3478
AHFS/Drugs.com	Monograph
MedlinePlus	a605032
License data	EU EMA: by INN US DailyMed: Sodium oxybate
Routes of administration	By mouth
ATC code	N07XX04 (WHO)
Legal status
Legal status	AU: S8 (Controlled drug) CA: CDSA Schedule III/FDA Schedule G Part I UK: CD POM (Schedule 2) US: WARNINGSchedule I / Schedule III EU: Rx-only In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	88%
Protein binding	<1%
Elimination half-life	0.5 to 1 hour.
Excretion	Almost entirely by biotransformation to carbon dioxide, which is then eliminated by expiration
Identifiers
IUPAC name Sodium 4-hydroxybutanoate
CAS Number	502-85-2 N
PubChem CID	23663870
IUPHAR/BPS	4711
DrugBank	DB01440 Y
ChemSpider	9983 Y
UNII	7G33012534
KEGG	D05866 Y
ChEMBL	ChEMBL1200682 N
CompTox Dashboard (EPA)	DTXSID3048940
ECHA InfoCard	100.007.231
Chemical and physical data
Formula	C4H7NaO3
Molar mass	126.087 g·mol−1
3D model (JSmol)	Interactive image
SMILES [Na+].[O-]C(=O)CCCO
InChI InChI=1S/C4H8O3.Na/c5-3-1-2-4(6)7;/h5H,1-3H2,(H,6,7);/q;+1/p-1 Y Key:XYGBKMMCQDZQOZ-UHFFFAOYSA-M Y
NY (what is this?)  (verify)

Sodium oxybate, sold under the brand name Xyrem among others, is a medication used to treat symptoms of narcolepsy: sudden muscle weakness and excessive daytime sleepiness. It is used sometimes in France and Italy as an anesthetic given intravenously; it is also approved and used in Italy and in Austria to treat alcohol dependence and alcohol withdrawal syndrome.

Sodium oxybate is the sodium salt of γ-hydroxybutyric acid (GHB). The clinical trials for narcolepsy were conducted just as abuse of GHB as a club drug and date rape drug became a matter of public concern; in 2000 GHB was made a Schedule I controlled substance, while sodium oxybate, when used under an FDA NDA or IND application, was classified as a Schedule III controlled substance for medicinal use under the Controlled Substances Act, with illicit use subject to Schedule I penalties.

Sodium oxybate was approved for use by the US Food and Drug Administration (FDA) to treat symptoms of narcolepsy in 2002, with a strict risk evaluation and mitigation strategy (REMS) program mandated by the FDA. The US label for sodium oxybate also has a black box warning because it is a central nervous system depressant and may cause respiratory depression, seizures, coma, or death, especially if used in combination with other central nervous system depressants, such as alcohol and its use may cause dependence. In Canada and the European Union it was classified as a Schedule III and a Schedule IV controlled substance, respectively.

It was approved for treating symptoms of narcolepsy in the European Union in 2005.

Orphan Medical had developed it and was acquired by Jazz Pharmaceuticals in 2005. The drug is marketed in Europe by UCB. Jazz Pharmaceuticals raised the price of the drug dramatically after it acquired Orphan, and paid a $20M fine for off-label marketing of the drug in 2007.

Medical use

Clinical use of sodium oxybate was introduced in Europe in 1964, as anesthetic given intravenously but it was not widely used since it sometimes caused seizures; as of 2006, it was still authorized for this use in France and Italy but not widely used.

The major use of sodium oxybate is in treating two of the symptoms of narcolepsy – cataplexy (sudden muscle weakness) and excessive daytime sleepiness. Reviews of sodium oxybate concluded that it is well tolerated and associated with "significant reductions in cataplexy and daytime sleepiness," and that its effectiveness "in treating major, clinically relevant narcolepsy symptoms and sleep architecture abnormalities" has been established. However, because of the risks of abuse associated with this medication, it is available in the US only through a REMS program mandated by the FDA. The program requires that providers who prescribe it are certified to do so, that it is dispensed only from a central pharmacy that is certified to do so, and people to whom it is prescribed must be enrolled in a program for the drug and must document that they are using the drug safely.

Investigations of its use in dealing with alcohol withdrawal syndrome and in the maintenance of abstinence have begun in 1989 12bis in Italy where it was then approved in these indications in 1991. It has also been approved for use in Austria. Over the years, several studies were conducted to further substantiate sodium oxybate efficacy in these indications. Results of small studies suggest it may be "better than naltrexone and disulfiram regarding abstinence maintenance and prevention of craving in the medium term i.e. 3-12 months." In a 2014 review, Gillian Keating described sodium oxybate as a "useful option for the treatment of alcohol withdrawal syndrome and for the maintenance of abstinence in alcohol dependence." However, a 2018 review recognised the evidence for its efficacy but noted safety concerns and concluded that "studies are still limited and investigations including a larger number of patients are needed."

In this context, a study published in 2019 analyzed safety data from 40 clinical trials and from pharmacovigilance database covering around 260,000 alcohol dependent patients treated with sodium oxybate in Italy and Austria. Results showed that sodium oxybate was well-tolerated, risks were controlled, and no safety concerns were reported. The sodium oxybate approved dose regimen for the treatment of alcohol dependence (i.e. around 3.2g/day) is lower than the one for the treatment of narcolepsy (4.5-9g/night). In 2023, a PhD thesis conducted at the University of Amsterdam, presented results of large clinical trials, including a phase 3 trial, and of meta-analyses which confirmed the efficacy, the good tolerance and the safety of sodium oxybate in the maintenance of abstinence, particularly in severe alcohol-dependent patients. A group of international researchers has also considered in 2018 that “sodium oxybate has an excellent risk benefit ratio for this indication” and that it is “a very promising therapeutic option for the most severe alcohol-dependent patients and may provide substantial clinical and public health benefit and costs”.

Multiple trials have shown sodium oxybate to be effective in treating important symptoms of fibromyalgia such as pain and poor sleep structure however in 2010 the FDA voted unanimously against with commenters citing potential for abuse as a street drug.

Pregnant women should not take it, and women should not become pregnant while taking it. It is excreted in breast milk and should not be used by breast feeding mothers.

Adverse effects

The US label for sodium oxybate has a black box warning because it is a central nervous system depressant (CNS depressant) and for its potential for abuse. Other potential adverse side effects include respiratory depression, seizures, coma, and death, especially when it is taken in combination with other CNS depressants such as alcohol. Cases of severe dependence and cravings have been reported with excessive and illicit use of this medication. GHB, the protonated (acidic) form of this salt, has been used to commit drug-facilitated sexual assault and date rape, though the illicit form of GHB typically has different characteristics from pharmaceutical-grade sodium oxybate.

It causes dizziness, nausea, and headache in 10% to 20% of people who take it; nausea is more common in women than men.

Between 1% and 10% of people experience nasal congestion, runny nose, or sore throat, loss of appetite, distorted sense of taste, cataplexy, weakness, nervousness or anxiety, depressed mood, nightmares or abnormal dreams, sleep paralysis, sleepwalking, or other sleep disturbances including insomnia, sleepiness or sedation, falls, vertigo, tremor, balance disorder, cognitive issues including disturbance in attention, confusion or disorientation, numbed sense of touch, tingling, blurred vision, heart palpitations, high blood pressure, shortness of breath, snoring, vomiting, diarrhea, stomach pain, excessive sweating, rashes, joint pain, muscle pain, back pain, muscle spasms, bedwetting, urinary incontinence, and swelling of the limbs.

Overdose

Reports of overdose in medical literature are generally from abuse, and often involve other drugs as well. Symptoms include vomiting, excessive sweating, periods of stopped breathing, seizures, agitation, loss of psychomotor skills, and coma. Overdose can lead to death due to respiratory depression. People who overdose may die from asphyxiation resulting from choking on vomit and/or aspiration. People that have overdosed or suspected of overdosing may need to be made to vomit, be intubated, or/and put on a ventilator.

Interactions

It should not be used with other drugs that are CNS depressants like alcohol or sedatives. Use with divalproex results in about a 25% increase in the availability of sodium oxybate.

Pharmacology

Main article: gamma-Hydroxybutyric acid

The mechanism of action of sodium oxybate is unknown. GHB is a normal metabolite of GABA that interacts with the GABA_B receptor.

Sodium oxybate is rapidly absorbed and is about 88% bioavailable; very little is bound to plasma protein. The average time to peak plasma concentration ranges from 0.5 to 1.25 hours. Very little of the drug is excreted; instead, it is mostly metabolized through several steps into carbon dioxide and water.

Chemistry

Sodium oxybate is the sodium salt of γ-hydroxybutyric acid (GHB). Its systematic chemical name is sodium 4-hydroxybutanoate, though synonyms like sodium γ-hydroxybutyrate are commonly used. Its condensed structural formula is HOCH
₂CH
₂CH
₂CO
₂Na (molecular formula: C
₄H
₇NaO
₃) and its molar mass is 126.09 g mol⁻¹. It is highly hydrophilic. Treating the salt with acid allows the carboxylic acid form of the compound, which is GHB, to be recovered.

History

Alexander Zaytsev worked on this chemical family and published work on it in 1874. The first extended research into sodium oxybate and its use in humans was conducted in the early 1960s by Henri Laborit to study the neurotransmitter GABA. It was studied for a range of uses, including obstetric surgery, during childbirth, and as an anxiolytic; there were anecdotal reports of it having antidepressant and aphrodisiac effects as well. It was also studied as an intravenous anesthetic agent and was marketed for that purpose starting in 1964 in Europe, but it was not widely adopted as it caused seizures; as of 2006, that use was still authorized in France and Italy but not widely used. sodium oxybate was also studied to treat alcohol addiction and for use in narcolepsy from the 1960s onwards.

In May 1990, GHB was introduced as a dietary supplement and was marketed to bodybuilders for help with weight control, as a sleep aid, and as a "replacement" for L-tryptophan, which was removed from the market in November 1989 when batches of it were found to cause eosinophilia-myalgia syndrome. By November of that year, 57 cases of illness caused by the GHB supplements had been reported to the Centers for Disease Control and Prevention, with people having taken up to three teaspoons of GHB; there were no deaths, but nine people needed care in an intensive care unit. The FDA issued a warning in November 1990 that the sale of GHB was illegal. GHB continued to be manufactured and sold illegally, and it and its analogs were adopted as a club drug and came to be used as a date rape drug. The DEA made seizures and the FDA reissued warnings several times throughout the 1990s.

At the same time, research on the use of sodium oxybate had formalized, as a company called Orphan Medical Inc. had filed an Investigational New Drug application and was running clinical trials with the intention of gaining regulatory approval for use to treat narcolepsy. In 1996, Orphan contracted with Lonza Group, a contract manufacturer for supply of the drug.

In 2000, the Hillory J. Farias and Samantha Reid Date-Rape Prevention Act of 2000 was signed into law in the US, which put GHB on Schedule I of the Controlled Substances Act, but sodium oxybate, when used under an IND or NDA from the US FDA, was considered a Schedule III substance, but with Schedule I trafficking penalties.

It was approved by the FDA, in 2002, under the brand name Xyrem with a strict risk control strategy to prevent drug diversion and control the risk of abuse by people to whom it was prescribed.

Orphan Medical licensed the right to market the drug in Europe to Celltech in 2003. In 2004, Celltech was acquired by UCB and in 2005 Jazz Pharmaceuticals acquired Orphan Medical.

In January 2007, Valeant announced that Jazz Pharmaceuticals had licensed the rights to market Xyrem in Canada to Valeant. Jazz Pharmaceuticals and Valeant terminated the agreement in 2017.

In July 2007, Jazz Pharmaceuticals and their subsidiary, Orphan Medical, pleaded guilty to a criminal charge of felony misbranding in their marketing of sodium oxybate; they also settled a civil suit at the same time. Jazz Pharmaceuticals paid $20 million in total and agreed to a corporate integrity agreement and to implement internal reforms. The FDA sent Jazz Pharmaceuticals an FDA warning letter about safety violations in September 2007.

In 2010, the FDA rejected Jazz Pharmaceuticals' New Drug Application for use of sodium oxybate in fibromyalgia.

In October 2011, the FDA sent Jazz Pharmaceuticals another FDA warning letter for failing to collect, evaluate, and promptly report adverse effects to the FDA after it started marketing the drug. It sent another letter in 2013 saying that the problems described in the 2011 letter appeared to be resolved.

In January 2017, the FDA approved the first generic sodium oxybate product for narcolepsy symptoms, which is also subject to the same REMS program conditions as the original. By April 2017, seven companies had filed Abbreviated New Drug Applications (ANDAs) with the FDA to market generic versions of Xyrem, which resulted in Jazz Pharmaceuticals filing patent infringement cases against them. Hikma Pharmaceuticals had been the first company to file an ANDA and Jazz Pharmaceuticals settled with them in April 2017; under the agreement Hikma could begin selling an authorized generic in 2023 under Jazz Pharmaceuticals' REMS, and would have five years of exclusivity, however, those conditions could change if Jazz Pharmaceuticals' patents were invalidated. In 2023, Jazz Pharmaceuticals licensed the right to produce an authorized generic of Xyrem to Hikma Pharmaceuticals, marketed as "Sodium Oxybate Oral Solution".

In May 2023, the FDA approved Lumryz, an extended-release oral suspension of sodium oxybate. Lumryz replaces the traditional twice-nightly dosage of instant-release sodium oxybate formulations (like Xyrem) with a single dose at bedtime.

Society and culture

Regulation

In the United States, GHB is a Schedule I controlled substance, while sodium oxybate, when used under an FDA NDA or IND application, is classified as a Schedule III controlled substance for medicinal use under the Controlled Substances Act, with illicit use subject to Schedule I penalties.

In Canada and the European Union, as of 2009, it is classified as a Schedule III and a Schedule IV controlled substance, respectively.

Cost

In the US, the cost (as of Q3 2015) of Xyrem is $5,468.09 per 180 mL bottle (500 mg/mL)(a 10 to 15-day supply) As of 2017 the cost of sodium oxybate in the UK was £540.00 to £1,080.00 for a thirty-day supply, which at typical doses is £6,500 to £13,100 per year.

Jazz Pharmaceuticals raised the price of Xyrem 841% earning a total of $569 million in 2013 and representing more than 50% of Jazz Pharmaceutical's revenues. In 2007 it cost $2.04; by 2014 it cost $19.40 per 1-milliliter dose. Jazz offers copay assistance to help patients access the expensive drug. According to DRX, a drug-data report published by Bloomberg, Jazz Pharmaceuticals price increase on Xyrem topped the list of price hikes in 2014.

Historically, orphan drugs cost more than other drugs and have received special treatment since the enactment of the US Orphan Drug Act of 1983. However, these steep price increases of orphan and other specialty drugs has come under scrutiny. The average cost of a specialty drug in the US was $65,000 annually in June 2013 (about $5,416 a month). The price of Xyrem in the US has inflated by an average of 40% annually since it became available as a prescription.

The first authorized generic sodium oxybate, produced by Hikma Pharmaceuticals, was made available in January of 2023.

In European Union countries, the government either provides national health insurance (as in the UK and Italy) or strictly regulates quasi-private social insurance funds (as in Germany, France, and the Netherlands). These government agencies are the sole purchaser (or regulator) of medical goods and services and have the power to set prices. The cost of pharmaceuticals, including sodium oxybate, tends to be lower in these countries.

NHS England authorises and pays for sodium oxybate by means of individual funding requests on the basis of exceptional circumstances. The British Department of Health pays for the medication for 80 patients who are taking legal action over problems linked to the use of the swine flu vaccine Pandemrix at a cost of £12,000 a year. As of 2016 there were many areas in the UK where NHS did not pay for it. In May 2016 they were ordered by the High Court to provide funding to treat a teenager with severe narcolepsy. The judge criticised their "thoroughly bad decision" and "absurd" policy discriminating against the girl when hundreds of other NHS patients already receive the drug.

Names

Sodium oxybate is the common name for the chemical; it has no international nonproprietary name (INN).

As of April 2018, sodium oxybate is sold under the following brands: Alcover (Italy), Gamma-OH (France), Natrii oxybutyras Kalceks (Latvia), Somsanit (Germany), Xyrem (many countries by Jazz Pharmaceuticals and UCB).

In 2023, the first authorized generic of Xyrem was made available in the US.

Research

Jazz Pharmaceuticals has been developing JZP-386, a deuterated analog of sodium oxybate. The company presented Phase I results in 2015, stating that deuterium-related effects made it necessary to do further formulation work as part of the drug's development.